Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue
+4.29%
EPS
+2.17%
Free cash flow
+27.0%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%
Market cap
$16.8B
P/E
71.9×
Fwd P/E
66.2×
Dividend yield
0.19%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. (RVTY) Revenue

Alert me on Revenue

Revvity Inc.'s revenue for fiscal 2025 was $2.9B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $2.9B. Over the past ten years it has ranged from $2.1B (fiscal 2015) to $3.8B (fiscal 2021); the current reading is higher than 73% of that period. Revvity Inc. ranks 13th of 47 Diagnostics & Research companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $2.9B 3.67%
FY2024 $2.8B 0.16%
FY2023 $2.8B (16.95%)
FY2022 $3.3B (13.48%)
FY2021 $3.8B 43.73%
FY2020 $2.7B (7.64%)
FY2019 $2.9B 3.80%
FY2018 $2.8B 23.08%
FY2017 $2.3B 6.69%
FY2016 $2.1B 0.51%

Quarterly newest first

Period Revenue Change
Sep 2026 $728.9M (0.11%)
Jun 2026 $729.7M 2.61%
Mar 2026 $711.1M (7.89%)
Dec 2025 $772.1M 10.46%
43 more quarters

Against its own ten years

Low $2.1B High $3.8B
Ten-year median $2.8B
Current reading's percentile 73

Revenue against peers

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on RVTY